| Appendix Cancers |
|
|
Cancer of the Appendix (also known as appendiceal cancer) occurs when cells in the appendix become abnormal and multiply without control. There are a range of different types of tumours and cancers which can start in the appendix. About two thirds of appendix tumours are carcinoid tumours which develop in hormone-producing cells that are present in many parts of the body, including the appendix. Mucinous cystadenocarcinoma account for about a fifth of appendix tumours, these produces mucin (a jelly-like substance). Pseudomyxoma Peritonei (PMP) is a more common name given to the "jelly belly" syndrome caused by mucinous adenoma and mucinous adenocarcinoma. Less common tumours of the appendix include signet-ring cell adenocarcinoma and paraganglioma. Treatment varies according to the type and stage of tumour.
Menu: Appendix Cancers
Information for Patients and the Public
Information for Health Professionals / Researchers
Latest Research Publications
Gastrointestinal Carcinoid Tumours
Gastrointestinal CancersInformation Patients and the Public (13 links)
- Gastrointestinal Carcinoid Tumors Treatment
National Cancer Institute
PDQ summaries are written and frequently updated by editorial boards of experts Further info. - Appendix Cancer
Cancer.Net
Content is peer reviewed and Cancer.Net has an Editorial Board of experts and advocates. Content is reviewed annually or as needed. Further info. - Pseudomyxoma peritonei
Cancer Research UK
CancerHelp information is examined by both expert and lay reviewers. Content is reviewed every 12 to 18 months. Further info.
Questions and asnwers - Pseudomyxoma peritonei
Macmillan Cancer Support
Content is developed by a team of information development nurses and content editors, and reviewed by health professionals. Further info. - Appendiceal Cancer Advocacy Network
Appendiceal Cancer Advocacy Network
A patient-based advocacy organization, founded in 2004, dedicated to serving the needs of those diagnosed with cancer of the appendix. - Appendix Cancer
Robert J. Miller, M.D - abourcancer.com
Short overview of appendix cancer and published abstract. - Appendix Cancer Connection
Appendix Cancer Connection
Founded by Carolyn Langlie-Lesnik RN BSN, a survivor of appendix cancer. The site includes information about the types of appendix cancer, treatment, survivors' stories, FAQ. - PMP Awareness Organization
PMP Awareness Organization
Promoting Awareness of PMP (Pseudomyxoma Peritonei), Appendiceal Cancer and other Peritoneal Surface Malignancies. - PMP Pals' Network
PMP Pals' Network
Support network and information about the various forms of appendix cancer. - PMP Research Foundation
PMP Research Foundation
A charitable organization founded in 2008 by a community of individuals affected by Pseudomyxoma Peritonei (PMP) and related Peritoneal Surface Malignancies (PSM). The site includes a FAQ and community information. - Pseudomyxoma Peritonei
The Christie NHS Foundation Trust
Detailed information on PMP from The Christie in Manchester, one of the two specialist PMP treatment centres in the UK. - Pseudomyxoma Survivor
Pseudomyxoma Survivor
A registered charity which provides a support network for survivors and carers of Pseudomyxoma Peritonei. For those that are newly diagnosed, there is buddy system, Pseudomyxoma Buddies, which is free of charge and available UK wide. - What is Appendiceal Cancer?
Shooting for a Cure
Shooting for a Cure raises money for the Ric Summers Appendical Cancer Research Fund, linked to the MD Anderson Cancer Center in Houston.
Information for Health Professionals / Researchers (4 links)
- PubMed search for publications about Appendiceal cancer - Limit search to: [Reviews]
PubMed Central search for free-access publications about Appendiceal cancer
MeSH term: appendiceal neoplasms
US National Library of Medicine
PubMed has over 22 million citations for biomedical literature from MEDLINE, life science journals, and online books. Constantly updated. - Gastrointestinal Carcinoid Tumors Treatment
National Cancer Institute
PDQ summaries are written and frequently updated by editorial boards of experts Further info. - Atlas of Appendix Cancer and Pseudomyxoma Peritonei
Washington Cancer Institute
A site by . Includes histopathology (with images), CT, clinical assessment, pharmacokinetics of intraperitoneal chemotherapy, morphology, cytoreductive surgery, perioperative intraperitoneal chemotherapy, and results of treatment. - Clinical Trials - Appendix carcinoma
National Cancer Institute
Latest Research Publications
This list of publications is regularly updated (Source: PubMed).
Transcription factor E3 protein-positive perivascular epithelioid cell tumor of the appendix presenting as acute appendicitis: a case report and review of the literature.
Arch Pathol Lab Med. 2013; 137(3):434-7 [PubMed]
Tumor staging but not grading is associated with adverse clinical outcome in neuroendocrine tumors of the appendix: a retrospective clinical pathologic analysis of 138 cases.
Am J Surg Pathol. 2013; 37(4):606-12 [PubMed]
Frequent GNAS mutations in low-grade appendiceal mucinous neoplasms.
Br J Cancer. 2013; 108(4):951-8 [PubMed] Article available free on PMC after 05/03/2014
METHODS: Thirty-five appendiceal mucinous neoplasms were analysed for GNAS and KRAS mutations. A functional analysis of mutant GNAS was performed using a colorectal cancer cell line.
RESULTS: A mutational analysis identified activating GNAS mutations in 16 of 32 low-grade appendiceal mucinous neoplasms (LAMNs) but in none of three mucinous adenocarcinomas (MACs). KRAS mutations were found in 30 LAMNs and in all MACs. We additionally analysed a total of 186 extra-appendiceal mucinous tumours and found that GNAS mutations were highly prevalent in intraductal papillary mucinous tumours of the pancreas (88%) but were rare or absent in mucinous tumours of the colorectum, ovary, lung and breast (0-9%). The prevalence of KRAS mutations was quite variable among the tumours. The introduction of the mutant GNAS into a colorectal cancer cell line markedly induced MUC2 and MUC5AC expression, but did not promote cell growth either in vitro or in vivo.
CONCLUSION: Activating GNAS mutations are a frequent and characteristic genetic abnormality of LAMN. Mutant GNAS might play a direct role in the prominent mucin production that is a hallmark of LAMN.
Intestinal obstruction secondary to appendiceal mucocele.
Chirurgia (Bucur). 2012 Nov-Dec; 107(6):802-4 [PubMed]
Management of the acute appendix mass: a survey of surgical practice.
Ir Med J. 2012; 105(9):303-5 [PubMed]
Primary mucinous borderline tumor of the vermiform appendix mimicking ovarian carcinoma; case report.
Eur J Gynaecol Oncol. 2012; 33(5):528-9 [PubMed]
CASE: We present a 71-year-old woman with primary mucinous borderline tumor of the vermiform appendix. She was misdiagnosed as an ovarian carcinoma patient and operated on by a gynecologic oncology team. Her frozen section analysis of an appendicial mass resulted as borderline tumor of appendix vermiformis, and right hemicolectomy, as is advised in invasive colon tumors, was not carried out.
CONCLUSION: Borderline mucinous tumor of the appendix vermiformis should be kept in mind in patients who have pseudomyxoma peritonei during surgery. Tumoral resection may be the definitive therapy in these patients.
Value of laparoscopy before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis.
Br J Surg. 2013; 100(2):285-92 [PubMed]
METHODS: Patients with peritoneal carcinomatosis from colorectal cancer or appendiceal cancer, pseudomyxoma peritonei or peritoneal mesothelioma referred to a single, national HIPEC centre were included prospectively between June 2006 and January 2012. From September 2010, preoperative evaluation also included a laparoscopy in patients deemed amenable to cytoreductive surgery and HIPEC after radiological evaluation, apart from those with pseudomyxoma peritonei with massive amounts of mucin.
RESULTS: In the period before laparoscopic evaluation, 70 patients underwent laparotomy of whom 39 (56 per cent) completed cytoreductive surgery and HIPEC. After the introduction of laparoscopic assessment, diagnostic laparoscopy was planned in 45 patients and successful in 43. The laparoscopic evaluation excluded 18 patients from surgery because of extensive disease, among other reasons. Laparoscopy was uneventful and associated with no deaths. Twenty-seven patients were considered amenable to cytoreductive surgery and HIPEC based on laparoscopic findings, of whom 17 completed this treatment; the disease was unresectable in the remaining ten patients. Of 13 patients who were not eligible for laparoscopic evaluation and were subjected to cytoreductive surgery plus HIPEC, 11 completed the procedure. The overall completion rate of cytoreductive surgery and HIPEC increased to 70 per cent (28 of 40) after the introduction of laparoscopic evaluation.
CONCLUSION: Diagnostic laparoscopy was valuable in preoperative evaluation of the extent of peritoneal carcinomatosis, and improved patient selection for cytoreductive surgery and HIPEC.
The role of appendectomy for mucinous ovarian neoplasms.
Am J Obstet Gynecol. 2013; 208(1):46.e1-4 [PubMed]
STUDY DESIGN: A retrospective chart review of patients operated on at our institution with the diagnosis of a mucinous neoplasm of the ovary or appendix.
RESULTS: A total of 327 cases were identified. Of the 309 women with mucinous ovarian neoplasms, 197 (64%) were benign, 68 (22%) low malignancy potential, and 44 (14%) were invasive. Of 155 appendectomies performed, only 1 metastatic low grade mucinous appendiceal tumor was found, but this appendix was grossly abnormal. There was no association between wound complications and appendectomy.
CONCLUSION: When a grossly normal appendix is removed during surgery for a mucinous ovarian neoplasm without evidence of pseudomyxoma peritonei, no primary or metastatic mucinous appendiceal tumors are found.
Neoplasms of the appendix: current treatment guidelines.
Hematol Oncol Clin North Am. 2012; 26(6):1261-90 [PubMed]
A rare case of primary extranodal marginal zone B-cell lymphoma of the ovary, fallopian tube, and appendix in the setting of endometriosis.
Am J Obstet Gynecol. 2013; 208(1):e12-4 [PubMed]
A novel complex KIT mutation in a gastrointestinal stromal tumor of the vermiform appendix.
Hum Pathol. 2013; 44(4):651-5 [PubMed]
Case study of appendiceal carcinoid during pregnancy.
J Med Life. 2012; 5(3):325-8 [PubMed] Article available free on PMC after 05/03/2014
Current status and future directions in appendiceal cancer with peritoneal dissemination.
Surg Oncol Clin N Am. 2012; 21(4):599-609 [PubMed]
Intussusception of the appendix induced by sessile serrated adenoma: a case report.
Turk Patoloji Derg. 2012; 28(3):290-2 [PubMed]
Delayed repeated intraperitoneal chemotherapy after cytoreductive surgery for colorectal and appendiceal carcinomatosis.
Dis Colon Rectum. 2012; 55(10):1044-52 [PubMed]
OBJECTIVE: The aim of this study was to evaluate the safety and feasibility of delayed repeated intraperitoneal chemotherapy after cytoreduction of colorectal and appendiceal carcinomatosis and pseudomyxoma peritonei.
DESIGN: This study constitutes a retrospective case series.
SETTING: This study was conducted at a single institution.
PATIENTS: A total of 31 patients with peritoneal carcinomatosis (23) and pseudomyxoma peritonei (8) were included.
INTERVENTIONS: Cytoreduction was followed by placement of an adhesion barrier and intraperitoneal catheters. Peritoneal scintigraphy preceded biweekly intraperitoneal 5-fluorouracil and systemic combination chemotherapy with leucovorin, fluorouracil, and oxaliplatin (FOLFOX).
MAIN OUTCOME MEASURES: The primary outcomes measured are safety, feasibility, and short-term survival.
RESULTS: Cytoreduction to a score of 0 to 1 was possible in 25 patients (80%). Complications occurred in 16 patients (51.6%) and were confined to grades I to III. There were no deaths, and no digestive fistulae occurred. Port malfunction or complication resulted in removal in 5 patients (16.1%). Intraperitoneal chemotherapy was possible in 83.8% of patients; 55% completed the full course. Peritoneal scintigraphy demonstrated free diffusion of tracer in 18 patients (58%), 4 (12.9%) had diffusion in each gutter with limited communication, 5 (16.1%) had limited diffusion around each catheter without communication, and 2 (6.5%) had no diffusion on scintigraphy. Overall survival for peritoneal carcinomatosis was 44.5% at 3 years (95% CI = 23%-65%).
LIMITATIONS: The nonrandomized nature of this study and the early experience are limitations.
CONCLUSIONS: Delayed repeated intraperitoneal and systemic chemotherapy after cytoreduction is feasible and has acceptable morbidity rates. Delayed intraperitoneal chemotherapy is possible in 83% of patients.
Neuroendocrine tumors of the appendix in children and adolescents.
Pediatr Blood Cancer. 2013; 60(1):65-70 [PubMed]
PROCEDURE: Clinical data of 237 children with appendical NET were prospectively analyzed.
RESULTS: The mean age at presentation was 13.0 years, while the mean follow-up time was 2.9 (0.0-12.8) years. The majority of tumors (70.9%) were located at the apex, and were smaller than or equal to 10 mm (72.7%). Tumor size was directly correlated with age. A second operation or primary lymph node sampling was done in 25.3% (N = 60) of the patients, and infiltration of the lymph nodes by tumor cells was found in nine of these patients (15%). All 237 patients are alive without tumor symptoms.
CONCLUSIONS: ROC analysis and subsequent calculations identified a tumor size of >15 mm as the optimal cut-off point for the prediction of metastatic spread into the lymph system, with a sensitivity of 77.8% and a specificity of 66.7%. Therefore, secondary right hemicolectomy in completely removed appendical NET is recommended only in tumors >15 mm in size. For incompletely removed tumors ≤15 mm a local follow-up resection with lymph node sampling is recommended.
Inflammatory myofibroblastic tumor appendix with concomitant mucosal dysplasia, simulating pseudomyxoma on preoperative aspiration cytology.
J Cancer Res Ther. 2012 Apr-Jun; 8(2):317-9 [PubMed]
Pseudomyxoma peritonei of 92 Chinese patients: clinical characteristics, pathological classification and prognostic factors.
World J Gastroenterol. 2012; 18(24):3081-8 [PubMed] Article available free on PMC after 05/03/2014
METHODS: The clinicopathologic features and follow-up data of 92 patients with PMP were reviewed and retrospectively analyzed. The cases were categorized into three groups: disseminated peritoneal adenomucinosis (DPAM), peritoneal mucinous carcinomatosis (PMCA), and peritoneal mucinous carcinomatosis with intermediate or discordant features (PMCA-I/D). The log-rank test was used to analyze survival for each group and various clinicopathological parameters. Multivariate Cox proportional-hazard models were constructed to determine the important factors associated with survival.
RESULTS: The median age at diagnosis was 51.9 years (range: 22-76 years). The median follow up was 124 mo. The 3-, 5- and 10-year survival rates were 74.0%, 67.4% and 49.1%, respectively. There were 49 (53.2%) patients with DPAM, 26 (28.3%) with PMCA-I and 17 (18.5%) with PMCA. Patients with DPAM, PMCA-I/D and PMCA exhibited statistically significant difference in survival (P = 0.001). The 3 year survival for DPAM, PMCAI/D and PMCA was 97.0%, 80.0% and 67.0%, respectively; the 5 year survival was 80.0%, 67.0% and 50.0%, respectively; and the 10 year survival was 65.0%, 28.0% and 14.0%, respectively. Survival rate was significantly lowest in patients < 40 age years of age (P = 0.011). Appendiceal tumor and extra-ovarian parenchymal organ involvement were significantly related to overall survival. Patients with appendiceal mucinous adenocarcinoma (MACA) showed the significantly poorer prognosis (P = 0.011). Multivariate analysis showed that pathological classification, age, appendiceal tumor were significant related to overall survival.
CONCLUSION: The clinical process "PMP" should be pathologically classified into DPAM, PMCA and PMCA-I/D. Pathological classification, age, appendiceal MACA are survival independent predictors in Chinese patients with PMP.
Varying malignant potential of appendiceal neuroendocrine tumors: importance of histologic subtype.
J Surg Oncol. 2013; 107(2):136-43 [PubMed]
METHODS: We compared characteristics and outcomes of these histologic subtypes. Patients with appendiceal NETs were identified from the National Cancer Database (1998-2007). Descriptive statistics were used to compare cohorts and associations between clinicopathologic factors and overall survival (OS) were examined using Cox proportional hazards models.
RESULTS: A total of 2,812 patients with appendiceal NETs were identified. The most common histologic subtype was GCT (59.6%), followed by MCT (32.1%), CGCC-A (6.9%), and others (1.4%). CGCC-A had a significantly higher incidence of lymph node metastases (odds ratio [OR], 3.2; 95% confidence interval [CI], 2.1-4.8) and distant metastases (OR, 6.0; 95% CI = 3.8-9.3) than GCT. The 5-year OS was 86.3% (95% CI, 81.4-89.9) for MCT, 77.6% (95% CI, 74.0-80.8) for GCT, and 56.3% (95% CI, 42.1-68.4) for CGCC-A (P < 0.0001).
CONCLUSION: Appendiceal NETs represent a spectrum of disease with varying malignant potential: MCT (low), GCT (intermediate), and CGCC-A (high). GCTs represent the most common subtype, whereas CGCC-As place the patient at highest risk for regional and distant metastases and have the worst prognosis.
Inflammatory markers in blood and serum tumor markers predict survival in patients with epithelial appendiceal neoplasms undergoing surgical cytoreduction and intraperitoneal chemotherapy.
Ann Surg. 2012; 256(2):342-9 [PubMed]
METHODS: Associations between baseline variables, tumor markers [CEA (carcinoembyronic antigen], CA125, CA199), inflammatory markers including neutrophils-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR), and C-reactive protein (CRP) with progression-free survival (PFS) and overall survival (OS) were examined in patients undergoing surgical cytoreduction and intraperitoneal chemotherapy for epithelial appendiceal neoplasm.
RESULTS: A total of 174 patients with epithelial appendiceal neoplasm (low-grade pseudomyxoma, n = 117; appendiceal cancer, n = 57) underwent cytoreduction. On univariate analysis, all 3 inflammatory and tumor markers predicted for both PFS and OS, respectively; NLR ≤ 2.6 (P = 0.01, P = 0.002), PLR ≤ 166 (P = 0.006, P = 0.016), CRP ≤ 12.5 (P = 0.001, P = 0.008), CEA (P < 0.001, P = 0.001), CA125 (P = 0.004, P < 0.001), CA199 (P < 0.001, P < 0.001). On multivariate analysis, there were no independent predictors of OS. PFS was independently associated with the presence of lymph node metastasis (P = 0.02), CA199 > 37 (P = 0.003), and a CRP > 12.5 (P = 0.013). A higher peritoneal cancer index (PCI > 24) was associated with elevation in CEA > 12, CA125 > 39, CA199 > 37, PLR > 166 and CRP > 12. The tumor histologic subtype was associated with CA 199 levels.
CONCLUSIONS: The results from this investigation suggest that preoperative inflammatory markers in blood and serologic tumor markers may predict outcomes and are associated with tumor biology in patients with epithelial appendiceal neoplasm undergoing cytoreduction and intraperitoneal chemotherapy treatment.
Delay of cytoreductive surgery and heated intraperitoneal chemotherapy in patients with appendiceal neoplasm.
Am Surg. 2012; 78(7):745-8 [PubMed]
Schistosomiasis may contribute to goblet cell carcinoid of the appendix.
J Parasitol. 2012; 98(3):565-8 [PubMed]
Resection of tumor from the supragastric lesser sac with peritonectomy.
Gynecol Oncol. 2012; 127(1):256 [PubMed]
The perforated appendiceal carcinoid in children: a surgical dilemma.
J Pediatr Surg. 2012; 47(6):1155-8 [PubMed]
Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
J Clin Oncol. 2012; 30(20):2449-56 [PubMed]
PATIENTS AND METHODS: A retrospective multi-institutional registry was established through collaborative efforts of participating units affiliated with the Peritoneal Surface Oncology Group International.
RESULTS: Two thousand two hundred ninety-eight patients from 16 specialized units underwent CRS for PMP. Treatment-related mortality was 2% and major operative complications occurred in 24% of patients. The median survival rate was 196 months (16.3 years) and the median progression-free survival rate was 98 months (8.2 years), with 10- and 15-year survival rates of 63% and 59%, respectively. Multivariate analysis identified prior chemotherapy treatment (P < .001), peritoneal mucinous carcinomatosis (PMCA) histopathologic subtype (P < .001), major postoperative complications (P = .008), high peritoneal cancer index (P = .013), debulking surgery (completeness of cytoreduction [CCR], 2 or 3; P < .001), and not using HIPEC (P = .030) as independent predictors for a poorer progression-free survival. Older age (P = .006), major postoperative complications (P < .001), debulking surgery (CCR 2 or 3; P < .001), prior chemotherapy treatment (P = .001), and PMCA histopathologic subtype (P < .001) were independent predictors of a poorer overall survival.
CONCLUSION: The combined modality strategy for PMP may be performed safely with acceptable morbidity and mortality in a specialized unit setting with 63% of patients surviving beyond 10 years. Minimizing nondefinitive operative and systemic chemotherapy treatments before definitive cytoreduction may facilitate the feasibility and improve the outcome of this therapy to achieve long-term survival. Optimal cytoreduction achieves the best outcomes.
Pseudomyxoma peritonei--case report.
Eur J Gynaecol Oncol. 2012; 33(2):227-9 [PubMed]
Appendiceal metastasis 10 years following 'curative' resection for low-grade primary endometrial carcinoma.
BMJ Case Rep. 2012; 2012 [PubMed]
Primary malignant mesothelioma of the appendix.
Intern Med. 2012; 51(9):1027-30 [PubMed]
Classification of and cytoreductive surgery for low-grade appendiceal mucinous neoplasms.
Br J Surg. 2012; 99(7):987-92 [PubMed]
METHODS: Clinicopathological details and treatment outcomes of patients with a LAMN and disease limited to the appendix or immediate periappendiceal tissues, referred to a national treatment centre between 2002 and 2009, were evaluated prospectively.
RESULTS: Of 379 patients with a diagnosis of PMP, 43 (median age 49 years) had LAMNs localized to the appendix and periappendiceal tissue. Thirty-two patients initially presented with symptoms of acute appendicitis or right iliac fossa pain. Two distinct lesions were identified: type I (disease confined to the appendiceal lumen) and type II (mucin and/or neoplastic epithelium in the appendiceal submucosa, wall and/or periappendiceal tissue, with or without perforation). Type I lesions were managed by a watch-and-wait surveillance policy with serial measurement of tumour markers and computed tomography in 14 of 16 patients. Seventeen of 27 patients with type II lesions underwent risk-reducing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy with low morbidity. After a median follow-up of 40 months, there was no disease progression in either treatment pathway.
CONCLUSION: This study identified two LAMN subtypes. Type II lesions have pathological features of increased risk for dissemination and should be considered for risk-reducing cytoreductive surgery.
Significance of acquired diverticular disease of the vermiform appendix: a marker of regional neoplasms?
J Clin Pathol. 2012; 65(7):638-42 [PubMed]
MATERIALS AND METHODS: The pathology database at Hvidovre Hospital was searched for appendix specimens, received between 2001 and 2010, coded for DA or for a space-occupying lesion. Slides were reviewed to determine DA status and the nature of lesions possibly causing DA.
RESULT: Among 4413 appendix specimens, DA were identified in 39 (0.9%, CI 0.6% to 1.2%) cases, 17 (43.6%, 28.0% to 59.2%) of which additionally harboured an appendiceal neoplasm/neoplastic precursor, whereas this figure was 1.2% (CI 0.9% to 1.6%) for non-DA specimens (p<0.0001). Six of the 39 DA specimens comprised incipient DA, three of which coexisted with appendiceal neoplasms. In addition, local/regional non-neoplastic lesions (six cases) and colorectal carcinomas (four cases) coexisted with DA.
CONCLUSION: DA has significance as a putative marker of local/regional neoplasms. Therefore, a DA specimen proved significantly more likely to harbour a neoplastic growth than a non-DA counterpart. Submission for microscopy of the entire DA specimen, whether transmural or only incipient, and a comment in the pathology report on the occasional concurrence of local/regional neoplasms in this setting seem appropriate. The observation of DA may thus provide a valuable contribution in the diagnostic process.
This page last updated: 22nd May 2013
Displaying links verified within last 2 weeks at time of update.
